Tiagabine
Tiagabine is an anti-seizure medicine taken by mouth as add-on treatment for partial seizures in adults and children 12 years and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 3 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Tiagabine (Gabitril) is an add-on medicine for partial seizures in people 12 and older, which works by stopping nerve cells from reabsorbing GABA, the brain's main calming messenger, and it is a less commonly chosen, neurologist-guided option that has been around for well over a decade and is available as a generic. Sleepiness, dizziness, low energy and trouble concentrating are what people notice most, which is why the dose is raised slowly. Report mood changes or thoughts of self-harm, worsening confusion or sleepiness, and any new or more frequent seizures to your prescriber right away. Never stop it suddenly, since that can make seizures more frequent.
Clinical pearls
- Take every dose with food, and if you miss several doses, call your prescriber because the dose build-up may need restarting.
- Carbamazepine, phenytoin, primidone and phenobarbital make the body clear tiagabine faster, so starting or stopping one may change your dose.
- Tell prescribers you take tiagabine before starting an antidepressant, antipsychotic, stimulant or narcotic, since these can make seizures easier to trigger.
- Mention any past status epilepticus (a seizure that will not stop), since many with that history had it again on tiagabine.
Patient information guide A plain-language walkthrough of Tiagabine, written from its FDA label.
What Tiagabine is used for
▾
Tiagabine is an anti-seizure medicine used in one way:
- Add-on (adjunctive) treatment of partial seizures in adults and children 12 years and older, in the Tiagabine Hydrochloride oral tablet products.
How Tiagabine works
▾
The precise way tiagabine prevents seizures is unknown. It is thought to block the re-uptake of GABA, the brain's main inhibitory (calming) messenger, into nerve cells. This leaves more GABA available to calm nearby nerve cells.
Lab studies suggest it acts mainly on GABA and has little effect on other brain chemicals such as dopamine or serotonin.
Tiagabine dosage
▾
Tiagabine tablets are taken by mouth with food, usually split into two to four doses a day. Your dose is raised slowly, and no loading dose is used.
- Your dose depends on whether you also take enzyme-inducing seizure medicines such as carbamazepine, phenytoin, primidone or phenobarbital.
- People not taking those medicines generally need lower doses and a slower build-up.
- If you miss a dose, don't double the next one. If you miss several, call your doctor.
- Your doctor may adjust your dose if your other seizure medicines change.
Dosing details from the FDA-approved label
From the Tiagabine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Induced adolescents 12 to 18 years old (already taking enzyme-inducing AEDs, e.g., carbamazepine, phenytoin, primidone, phenobarbital)
- Initiate at 4 mg once daily
- Total daily dose may be increased by 4 mg at the beginning of Week 2
- Thereafter may be increased by 4 to 8 mg at weekly intervals until clinical response is achieved or up to 32 mg/day, given in divided doses two to four times daily
- Maximum: 32 mg/day (doses above 32 mg/day have been tolerated in a small number of adolescent patients for a relatively short duration)
- Take with food; do not use a loading dose; modification of concomitant antiepilepsy drugs is not necessary unless clinically indicated
- Induced adults (already taking enzyme-inducing AEDs)
- Initiate at 4 mg once daily
- Total daily dose may be increased by 4 to 8 mg at weekly intervals until clinical response is achieved or up to 56 mg/day, given in divided doses two to four times daily
- Usual adult maintenance dose 32 to 56 mg/day in two to four divided doses
- Maximum: 56 mg/day (doses above 56 mg/day have not been systematically evaluated in adequate and well-controlled clinical trials)
- Take with food; experience is limited with total daily doses above 32 mg/day using twice daily dosing
- Non-induced adults and adolescents 12 years or older (taking only non-enzyme-inducing AEDs)
- Requires lower doses of tiagabine hydrochloride tablets than induced patients
- The label text gives no specific regimen here
- Estimated plasma concentration is more than twice that in patients receiving enzyme-inducing agents; may require slower titration
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION General: The blood level of tiagabine obtained after a given dose depends on whether the patient also is receiving a drug that induces the metabolism of tiagabine. The presence of an inducer means that the attained blood level will be substantially reduced. Dosing should take the presence of concomitant medications into account. Tiagabine hydrochloride tablets are recommended as adjunctive therapy for the treatment of partial seizures in patients 12 years and older. The following dosing recommendations apply to all patients taking tiagabine hydrochloride tablets: Tiagabine hydrochloride tablets are given orally and should be taken with food. Do not use a loading dose of tiagabine hydrochloride tablets Dose titration: Rapid escalation and/or large dose increments of tiagabine hydrochloride tablets should not be used. Missed dose(s): If the patient forgets to take the prescribed dose of tiagabine hydrochloride tablets at the scheduled time, the patient should not attempt to make up for the missed dose by increasing the next dose. If a patient has missed multiple doses, patient should refer back to his or her physician for possible re-titration as clinically indicated. Dosage adjustment of tiagabine hydrochloride tablets should be considered whenever a change in patient's enzyme-inducing status occurs as a result of the addition, discontinuation, or dose change of the enzyme-inducing agent. Induced Adults and Adolescents 12 Years or Older: The following dosing recommendations apply to patients who are already taking enzyme-inducing antiepilepsy drugs (AEDs) (e.g., carbamazepine, phenytoin, primidone, and phenobarbital). Such patients are considered induced patients when administering tiagabine hydrochloride tablets. In adolescents 12 to 18 years old, tiagabine hydrochloride tablets should be initiated at 4 mg once daily. Modification of concomitant antiepilepsy drugs is not necessary, unless clinically indicated. The total daily dose of tiagabine hydrochloride tablets may be increased by 4 mg at the beginning of Week 2. Thereafter, the total daily dose may be increased by 4 to 8 mg at weekly intervals until clinical response is achieved or up to 32 mg/day. The total daily dose should be given in divided doses two to four times daily.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Tiagabine side effects
▾
Most side effects were mild to moderate and often began as the dose was increased. Common ones include:
Common side effects
- Dizziness or light-headedness
- Weakness or lack of energy
- Sleepiness
- Nausea
- Nervousness or irritability
- Tremor (shaking)
- Stomach pain
- Trouble concentrating or paying attention
- Trouble with concentration or attention
When to get medical help
- Call your doctor right away if you have new or worsening depression, unusual mood or behavior changes, or thoughts of suicide or self-harm.
- Get medical help if you have a seizure and have never had epilepsy. Tiagabine can cause new seizures, even at low doses.
- Seek help for severe confusion, speech or language problems, or marked sleepiness that gets worse.
- Get emergency help for a seizure that won't stop (status epilepticus).
- Call your doctor if seizures become more frequent, especially after missed doses or stopping the medicine.
- Report severe skin reactions such as blistering.
Tiagabine warnings and precautions
▾
- New seizures: Tiagabine has been linked to new seizures and status epilepticus in people without epilepsy.
- Suicidal thoughts: Anti-seizure medicines raise this risk slightly. In pooled trials, about 1 extra case occurred per 530 people treated.
- Withdrawal seizures: Don't stop suddenly. It should be withdrawn gradually unless safety requires otherwise.
- Thinking and alertness: Problems with concentration, speech, confusion, sleepiness and fatigue can occur.
- Status epilepticus: Risk is higher in people who have had it before.
Tiagabine interactions
▾
Other medicines can change tiagabine levels, so tell your prescriber everything you take.
- Carbamazepine, phenytoin, primidone, phenobarbital: clear tiagabine faster, lowering its levels.
- Valproate: may raise the free amount of tiagabine, though the effect's importance is unknown.
- St. John's wort: may speed up tiagabine breakdown.
- Alcohol and triazolam: use cautiously because of added nervous system depression.
- Other highly protein-bound drugs: may compete with tiagabine.
Interactions listed in the FDA-approved label
From the Tiagabine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Phenytoin: Tiagabine had no effect on steady-state phenytoin plasma concentrations; tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme-inducing AEDs. Dosage adjustment of tiagabine should be considered whenever enzyme-inducing status changes.
- Carbamazepine: Tiagabine had no effect on steady-state concentrations of carbamazepine or its epoxide metabolite; tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme-inducing AEDs. Dosage adjustment of tiagabine should be considered whenever enzyme-inducing status changes.
- Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations; valproate decreased tiagabine binding in vitro from 96.3 to 94.8%, increasing free tiagabine concentration by approximately 40%, of unknown clinical relevance.
- Phenobarbital or Primidone: Tiagabine caused no systematic changes in phenobarbital or primidone concentrations compared to placebo; tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs. Dosage adjustment of tiagabine should be considered whenever enzyme-inducing status changes.
- Cimetidine: Cimetidine (800 mg/day) had no effect on tiagabine pharmacokinetics.
- Theophylline, warfarin, digoxin, oral contraceptives, antipyrine: No effect on the pharmacokinetics of theophylline, warfarin (prothrombin times not affected), digoxin, oral contraceptives or antipyrine was observed with tiagabine.
- Ethanol or Triazolam: No significant pharmacokinetic differences and no clinically important potentiation of pharmacodynamic effects, but possible additive effects of drugs that may depress the nervous system. Ethanol or triazolam should be used cautiously in combination with tiagabine.
- St. John's wort: Concomitant use may enhance the metabolism of tiagabine.
- Highly protein bound drugs: Tiagabine is 96% bound to human plasma protein and may interact with other highly protein bound compounds, potentially leading to higher free fractions of either tiagabine or the competing drug.
Read the label’s full interactions text
Drug Interactions In evaluating the potential for interactions among coadministered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration. Carbamazepine, phenytoin, primidone, and phenobarbital are generally classified as enzyme inducers; valproate and gabapentin are not. tiagabine hydrochloride is considered to be a non-enzyme inducing AED (see PRECAUTIONS, General, Use in Non-Induced Patients ). The drug interaction data described in this section were obtained from studies involving either healthy subjects or patients with epilepsy. Effects of Tiagabine Hydrochloride on other Antiepilepsy Drugs (AEDs): Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy. Carbamazepine : Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy. Valproate : Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations. Phenobarbital or Primidone: No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone. The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo. Effects of other Antiepilepsy Drugs (AEDs) on Tiagabine Hydrochloride: Carbamazepine : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme-inducing AEDs. Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme-inducing AEDs.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Tiagabine
▾
- Don't use it if you are allergic to tiagabine or its ingredients.
- It is approved only for people 12 years and older.
- Tell your doctor if you have a history of status epilepticus.
- Share your full medicine list, especially other seizure medicines and drugs that can lower the seizure threshold, like antidepressants, antipsychotics, stimulants and narcotics.
- Tell your doctor about any depression or mood changes.
Tiagabine overdose
▾
Overdose can cause sleepiness, confusion, agitation, trouble speaking, weakness, seizures including status epilepticus, and in serious cases coma or breathing problems. There is no specific antidote, and care is supportive. Call a Poison Control Center or emergency services right away.
What Tiagabine does in the body
▾
Tiagabine is believed to increase GABA available between nerve cells by blocking its uptake. In lab studies it prolonged GABA's calming signals and was effective in several animal seizure models. Its effect appeared to weaken at higher doses in some models.
How your body processes Tiagabine
▾
Tiagabine is absorbed rapidly and almost completely. Peak levels come in about 45 minutes when fasting, and food slows absorption without lowering the amount absorbed. Its half-life is about 7 to 9 hours, and it is shorter, about 2 to 5 hours, in people taking enzyme-inducing seizure medicines. It is highly bound to proteins in the blood and is mostly broken down by the liver.
How to store Tiagabine
▾
Store at 20° to 25°C (68° to 77°F). Protect from light and moisture.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Tiagabine
214 supplements and herbal products have documented interactions with Tiagabine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 9
- Moderate · 157
- Minor · 48
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Tiagabine has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Tiagabine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Tiagabine — the kind of thing our pharmacy team would talk through with you at the counter.
What is tiagabine for?
▾
How should I take it?
▾
What if I miss a dose?
▾
Can I stop it if I feel fine?
▾
What side effects should I expect?
▾
Can I drink alcohol or take other medicines with it?
▾
Is Tiagabine available over the counter?
▾
When was Tiagabine first available?
▾
Who makes Tiagabine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Tiagabine on HelloPharmacist
Tiagabine forms and strengths (how it comes)
Tiagabine is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Tiagabine Hydrochloride tablets are used as add-on therapy for partial seizures in adults and children 12 years and older.
- Tiagabine Hydrochloride tablets are taken by mouth with food.
- Tiagabine Hydrochloride tablets should not be started with a loading dose or raised quickly.
- Tiagabine Hydrochloride tablets are usually given in divided doses two to four times daily.
- If you miss a dose of Tiagabine Hydrochloride tablets, don't make it up by increasing the next dose.
Tiagabine on the U.S. market: products, makers and brands
How Tiagabine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
4 companies list 14 Tiagabine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1997. Brand names on the directory include Gabitril; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (2) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Tiagabine is used (Medicaid data)
A general measure of how commonly Tiagabine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Tiagabine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Tiagabine prescribed? Of the 1,601 medications we measure, Tiagabine ranks #1,164 by Medicaid prescriptions — more than 27% of them.
Utilization by Tiagabine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
tiagabine hydrochloride 4 MG Oral Tablet Most dispensed
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1299917
tiagabine hydrochloride 2 MG Oral Tablet
Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1299911
tiagabine hydrochloride 12 MG Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1299903
tiagabine hydrochloride 16 MG Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1299909
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Tiagabine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 34 listed Tiagabine NDCs with Medicaid activity.
Compare Tiagabine products
A representative set of FDA-listed product records for Tiagabine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 2 mg | Oral | Cephalon, LLC | NDA | View NDC → |
| 4 mg | Oral | Cephalon, LLC | NDA | View NDC → |
| 12 mg | Oral | Cephalon, LLC | NDA | View NDC → |
| 16 mg | Oral | Cephalon, LLC | NDA | View NDC → |
| 2 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 4 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 12 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 16 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 2 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 4 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 4 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 12 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 16 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
Showing 14 of 14 products — FDA National Drug Code Directory. See every product, package size and price: browse all 14 Tiagabine NDCs →
Tiagabine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tiagabine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tiagabine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Tiagabine FDA approval history
How Tiagabine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Tiagabine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Tiagabine recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highw… Lots: Lot HAC3339A, Expires 07/2023 FDA record D-0914-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 31914 1 dose form · 8 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 374123In current FDA listingsClinical drug / strength (SCD) hydrochloride 10 MGRxCUI 1299900hydrochloride 12 MGRxCUI 1299903hydrochloride 15 MGRxCUI 1299906hydrochloride 16 MGRxCUI 1299909hydrochloride 2 MGRxCUI 1299911hydrochloride 20 MGRxCUI 1299914hydrochloride 4 MGRxCUI 1299917hydrochloride 5 MGRxCUI 1299919
Look up RxCUI 31914 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Tiagabine supply and shortage status
Whether Tiagabine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Tiagabine costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 2 mg | $2.62 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 4 mg | $2.52 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 12 mg | $6.62 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 16 mg | $6.03 per tablet | NDC details & price history |
| Tablet · Oral | 2 mg | $2.62 per tablet | NDC details & price history |
| Tablet · Oral | 4 mg | $2.52 per tablet | NDC details & price history |
| Tablet · Oral | 12 mg | $6.62 per tablet | NDC details & price history |
| Tablet · Oral | 16 mg | $6.03 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Tiagabine brand names
Tiagabine is sold under one brand name in the FDA directory — Gabitril. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Tiagabine: manufacturers and labelers
4 companies list Tiagabine products with the FDA. By number of product records, the largest are Cephalon, LLC, Novadoz Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Tiagabine drug class (RxNorm)
Tiagabine belongs to the Anti-epileptic Agent class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Tiagabine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →